Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02060188

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread — CheckMate142  

Microsatellite Stable Colorectal Cancer Clinical Trial

Official title:
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer

Clinical Trial Summary

The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has spread, and who have a specific biomarker in their tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Colorectal Neoplasms
  • Microsatellite Stable Colorectal Cancer
  • Microsatellite Unstable Colorectal Cancer
  • Mismatch Repair Deficient Colorectal Cancer
  • Mismatch Repair Proficient Colorectal Cancer
Clinical Trial Details
NCT number NCT02060188
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 12, 2014
Completion date June 28, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03658772 - Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer Phase 1
Active, not recruiting NCT03891953 - Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Phase 1
Recruiting NCT04895709 - A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03104439 - Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Phase 2
Terminated NCT04301011 - Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04332653 - NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT04060342 - GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Phase 1
Not yet recruiting NCT06444815 - A Study of VET3-TGI in Patients With Solid Tumors Phase 1
Completed NCT03473925 - Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Phase 2